10-K: OS Therapies Reports on Capital Structure, Clinical Trial Progress, and Acquisition Strategy in Annual Filing

OS Therapies provides an update on its financial standing, clinical trial outcomes, and strategic moves, including an acquisition, in its annual report.

Summary

• OS Therapies Incorporated, a clinical-stage biopharmaceutical company, has filed its annual report on Form 10-K.
• The company is focused on developing treatments for Osteosarcoma and other solid tumors, with its lead product candidate, OST-HER2, in Phase IIb clinical development.
• OST-tADC, a next-generation tunable drug conjugate platform, is in preclinical development.
• A Phase IIb clinical trial for OST-HER2 achieved its primary endpoint with statistical significance, showing a higher proportion of event-free survival at 12 months compared to a historical control group (33% vs. 20%).
• The company plans to request a meeting with the FDA to discuss the data and the path to a BLA submission in the second quarter of 2025.
• OS Therapies entered into an agreement to acquire HER2 assets from Ayala Pharmaceuticals, including two IND filings with the FDA, expected to close in the second quarter of 2025.
• The company completed a private placement, raising approximately $7.1 million in gross proceeds.
• As of March 28, 2025, the company had four full-time and one part-time employee.
• The company's independent registered public accounting firm has expressed substantial doubt about its ability to continue as a going concern.
• The company had federal and state NOLs of approximately $22.2 million as of December 31, 2024.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. Positive clinical trial results and strategic acquisitions are offset by concerns about the company's financial stability and internal controls.

Positives

• The Phase IIb clinical trial for OST-HER2 met its primary endpoint with statistical significance.
• OST-HER2 demonstrated a favorable safety profile in the Phase IIb clinical trial.
• The company is expanding its pipeline through the acquisition of HER2 assets from Ayala Pharmaceuticals.
• The company successfully raised capital through a private placement.
• Trial results showed a higher proportion of OST-HER2 treated patients were alive at the 12-month (91% vs. 80%) and 24-month (61% vs. 40%) post-resection timepoints relative to the Published Control.
• Notably, 100% of patients who were disease-free at 12 months remained alive at 12, 18, 24, and 30 months at their last follow-up.

Negatives

• The company's independent registered public accounting firm has expressed substantial doubt about its ability to continue as a going concern.
• The company has incurred significant operating losses and expects to continue to do so.
• The company has not generated any revenue to date from drug sales.
• The company's internal control over financial reporting was not effective as of the year ended December 31, 2024 due inadequate segregation of duties within account processes due to limited personnel, as well as insufficient written policies and procedures for accounting, IT, and financial reporting and record keeping.

Risks

• The company's future success depends heavily on the success of its lead product candidates, OST-HER2 and OST-tADC.
• The company may not be able to obtain regulatory approval for, or successfully commercialize, any of its current or future product candidates.
• The company may experience delays or difficulties in the enrollment of patients in clinical trials.
• The company's current or future product candidates may cause adverse or other undesirable side effects.
• The company may not be able to obtain or maintain orphan drug designation or exclusivity for any product candidates.
• The company may face substantial competition from other companies developing or marketing treatments for rare diseases and cancers.
• The company's ability to utilize its net operating loss carryforwards and certain other tax attributes in the future may be limited.
• The company will incur increased costs as a result of operating as a public company, and its management will be required to devote substantial time to new compliance initiatives.

Future Outlook

The company expects to incur significant expenses and operating losses over the next several years and for the foreseeable future as it continues to invest in research and development of its programs.

Management Comments

• Management believes that the net proceeds from the private placements and initial public offering, together with existing cash, will enable the company to fund its operating expenses and capital expenditure requirements for the next nine to 12 months.

Industry Context

The announcement highlights the ongoing interest in developing new treatments for rare cancers like Osteosarcoma, where there has been limited innovation in recent decades. The acquisition of HER2 assets reflects a broader trend of companies seeking to expand their oncology pipelines and leverage promising technologies.

Comparison to Industry Standards

• The reported 33% event-free survival rate at 12 months in the OST-HER2 Phase IIb trial compares favorably to the 20% rate in the historical control group, suggesting a potential improvement over existing standards of care.
• Companies like AstraZeneca, Y-mAbs Therapeutics, and MD Anderson Cancer Center are also developing product candidates for Osteosarcoma, indicating a competitive landscape.
• The company's reliance on third-party manufacturers is a common practice in the biopharmaceutical industry, particularly for smaller companies that lack their own manufacturing facilities.
• The company's focus on orphan drug designation and rare pediatric disease designation is a strategy often employed by companies developing treatments for rare diseases to secure market exclusivity and other benefits.

Legal Proceedings

• The Company is currently in arbitration for a claim brought by its former investment advisor. The claim is for underwriter compensation for the Companys initial public offering in August 2024. The Company believes the claim is meritless as it awaits a formal meeting.

Related Party Transactions

• John Ciccio and Theodore F. Search, Pharm.D., members of our board of directors, are members of the board of managers of Mill River Partners LLC.
• We had a bill in accounts payable of $26,765 for the period ended December 31, 2024 and $32,102 for the period ended December 31, 2023 to Shore Accountants MD Inc., an outside accounting firm that handles payroll and bookkeeping and is 100% owned by Mr. Christopher Acevedo, our Chief Financial Officer.
• On December 31, 2024 and December 31, 2023, we had a payroll payable to Mr. Paul Romness, our Chief Executive Officer, of $8,871 and $300,000, respectively, and related payroll taxes payable of $88,386 and $7,830, respectively.

Stakeholder Impact

• Shareholders: Dilution from potential future equity issuances, but potential for increased value if product candidates are successful.
• Employees: Job security dependent on the company's financial stability and success in developing and commercializing its product candidates.
• Patients: Potential for new and improved treatment options for Osteosarcoma and other solid tumors.
• Creditors: Risk of non-payment if the company is unable to secure additional funding or generate revenue.

Next Steps

• Request a Type B or Type C FDA meeting in the first quarter of 2025 to discuss the data and the path to a BLA.
• Submit a BLA with the FDA CBER for approval to market the drug candidate in the second quarter of 2025.
• Conclude pre-clinical and toxicology trials with the lead drug candidate for OST-tADC (OST-tADC-A, Exatecan-silanol-FRa), and file for an IND to initiate a Phase I trial in ovarian cancer and other folate receptor alpha overexpressing cancers like endometrial cancer and some osteosarcomas.
• Obtain marketing approval for OST-HER2 in Osteosarcoma, then quickly pivot to a master protocol within breast, esophageal, lung and other solid tumors where metastases express HER2 that could be targeted by immune cells.

Key Dates

Keywords

OST-HER2, OST-tADC, Osteosarcoma, Clinical Trial, FDA, BLA, Acquisition, Private Placement, Biopharmaceutical, Orphan Drug Designation, HER2 Assets, Regulatory Approval